Immuneering reports $150.2M cash; IND for IMM-1-104 expected Q3 2022

Immuneering Corp

Net loss Q4 2021: $10.8M ($0.42/share) vs $5.8M ($1.18/share) Q4 2020; full year loss $33.5M.
Cash and equivalents $150.2M as of Dec 31, 2021; expected cash runway into Q3 2024.
2022 GAAP operating expense guidance $55M-$60M; includes non-cash stock-based compensation.
IMM-1-104 IND filing expected Q3 2022, first patient enrollment in Phase 1 trial Q4 2022.
IMM-6-415 designated as drug candidate; IND-enabling studies underway, filing expected 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.